Roche: Important De-Risking Of CT-388 In Obesity, Petrelintide Is Next

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.Roche ( RHHBY ) reported positive phase 2 results of CT-388 in patients with obesity. The ...